Product Information
PIMECROLIMUS 1% CREAM is a generic product labeled by Glenmark Pharmaceuticals Inc., USA, priced at $3.3149 per GM under NDC 68462060935. Its NADAC has been published 365 times since Oct 9, 2019.
FDA first approved this application on Aug 29, 2019. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
10 mg/g
Manufacturer
Glenmark Pharmaceuticals Inc., USANDC
68462060935
Classification
Generic
Dosage Form
CREAM
Route
TOPICAL
Effective Date
9/23/2026
Active Ingredients
PIMECROLIMUSApproval Type
Generic (ANDA)
FDA Application
ANDA211769FDA Approved
8/29/2019
TE Code
AB
On Market Since
8/29/2019
Pharmacological Classes
Price Statistics
The NADAC for PIMECROLIMUS 1% CREAM has been published 365 times since Oct 9, 2019, and over the history we have for it it has declined 46.9%. The table below summarizes its recorded NADAC range and movement.
| Current price | $3.3149 per GM |
|---|---|
| All-time high | $7.5124 (Apr 15, 2020) |
| All-time low | $2.6485 (Nov 20, 2024) |
| 52-week high | $3.3825 |
| 52-week low | $2.6659 |
| Median price | $4.1325 |
| Average price | $4.4196 |
| Largest weekly change | +28.4% (Jun 19, 2024) |
| Weeks tracked | 365 |
| Tracking since | Oct 9, 2019 |
Generic Alternatives
The matcher finds 2 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 25% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Glenmark Pharmaceuticals Inc., USA manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Pimecrolimus market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Calcineurin Inhibitor Immunosuppressant class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of PIMECROLIMUS 1% CREAM?
The current National Average Drug Acquisition Cost (NADAC) for PIMECROLIMUS 1% CREAM, manufactured by Glenmark Pharmaceuticals Inc., USA, is $3.3149 per GM (NDC 68462060935), effective Sep 30, 2026.
How has the price of PIMECROLIMUS 1% CREAM changed over time?
Over the history we have for it, the NADAC for PIMECROLIMUS 1% CREAM has declined 46.9%. It has been tracked across 365 weekly CMS publications since Oct 9, 2019.
What are the highest and lowest recorded NADAC prices for PIMECROLIMUS 1% CREAM?
Since Oct 9, 2019, the NADAC for PIMECROLIMUS 1% CREAM has ranged from a low of $2.6485 (Nov 20, 2024) to a high of $7.5124 (Apr 15, 2020), with a median of $4.1325 per GM.
Are there cheaper alternatives to PIMECROLIMUS 1% CREAM?
Yes. 2 manufacturers publish a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, PIMECROLIMUS 1% CREAM, is $2.4853 per GM — about 25% below PIMECROLIMUS 1% CREAM.
Who manufactures PIMECROLIMUS 1% CREAM?
PIMECROLIMUS 1% CREAM (NDC 68462060935) is labeled by Glenmark Pharmaceuticals Inc., USA, and CMS classifies it as a generic product.